Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 59

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 59
---
 assuming we will continue as a going concern. Since our
inception, we have incurred net losses and experienced negative cash flows from operations. To date, our primary sources of capital have
been through private placements of equity securities and convertible debt and the Sales Agreement with A.G.P. During the years ended December
31, 2024 and 2023, we incurred operating losses of $15.4 million and $5.3 million, respectively.

Our
primary uses of cash are to fund our operations as we continue to grow our business. We will require a significant amount of cash
for expenditures as we invest in ongoing research and development and business operations. Until such time we can generate
significant revenue from the successful approval and commercialization of a product candidate, we expect to finance our cash needs for
ongoing research and development and business operations through public or private equity or debt financings or other capital
sources, including strategic partnerships. However, we may be unable to raise additional funds or enter into such other
arrangements, when needed, on favorable terms or at all. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, the ownership interest of our stockholders will be, or could be, diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing
and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise
additional funds through equity or debt financings when needed, we may be required to delay, limit, or substantially reduce research
and development efforts all of which could have a material adverse effect on the Company and its financial results.

While
the Company believes in the viability of its ability to raise additional funds, there can be no assurances to that effect. We have based
our estimates on assumptions of operating costs that may prove to be wrong. As a result, we could deplete our capital resources sooner
than we currently expect. If, for any reason, our expenses differ materially from our assumptions or we utilize our cash more quickly
than anticipated, or if we are unable to obtain funding on a timely basis we may be required to revise our business plan and strategy,
which may result in significantly curtailing, delaying or discontinuing one or more of our research or development programs or the commercialization